Evidence map›Paper›PMID 23772639›Full record

ArticleLeukemia & lymphoma2014

Molecular characteristics of diffuse large B-cell lymphoma in human immunodeficiency virus-infected and -uninfected patients in the pre-highly active antiretroviral therapy and pre-rituximab era.

Lindsay M Morton, Clara J Kim, Lawrence M Weiss, Kishor Bhatia, Myles Cockburn, Debra Hawes, Sophia S Wang, Cindy Chang, Sean F Altekruse, Eric A Engels and 1 more

Open access · greenAbstract read
In one paragraph

Article in Leukemia & lymphoma, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
2.3field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 25 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Expression of HIV-1 matrix protein p17 and association with B-cell lymphoma in HIV-1 transgenic mice.Proceedings of the National Academy of Sciences of the United States of America · 2016
    Article
  13. Review
  14. A comparative study of molecular characteristics of diffuse large B-cell lymphoma from patients with and without human immunodeficiency virus infection.Clinical cancer research : an official journal of the American Association for Cancer Research · 2015
    Article
  15. Review
  16. SEER cancer registry biospecimen research: yesterday and tomorrow.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2014
    Review
  17. Lymphoma immune reconstitution inflammatory syndrome in the center for AIDS research network of integrated clinical systems cohort.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2014
    Article
  18. Moving forward in HIV-associated cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2014
    Article
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 6 institutions in 1 country.

Lindsay M MortonDivision of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, DHHS , Rockville, MD , USA.
Clara J Kim
Lawrence M Weiss
Kishor Bhatia
Myles Cockburn
Debra Hawes
Sophia S Wang
Cindy Chang
Sean F Altekruse
Eric A Engels
Wendy Cozen
National Cancer Institute · USUniversity of Southern California · USDivision of Cancer Epidemiology and GeneticsCity of Hope · USCity Of Hope National Medical Center · USUnited States Department of Health and Human Services · US

Funding

Translational Research Support CoreP30ES007048 · NIEHS · UNIVERSITY OF SOUTHERN CALIFORNIA · PI Joseph Leo Wiemels · 1996 to 2026
$46.4M
Infections, immunity, and inflammation in cancerZIACP010150 · NCI · DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS · PI ENGELS, ERIC A · 2009 to 2025
$24.0M
CALIFORNIA'S PARTICIPATION IN THE NATIONAL CANCER PREVENTION AND CONTRO PROGRAMU58DP000807 · DP · PUBLIC HEALTH INSTITUTE · PI SNIPES, KURT P · 2007 to 2011
$22.5M
Infections, immunity, and inflammation in cancerZ01CP010150 · NCI · DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS · PI ENGELS, ERIC A · 2000 to 2008
$3.0M
Intramural NIH HHS Z01 CP010150NCCDPHP CDC HHS 1U58DP000807-3NCI NIH HHS N01-PC-2010-00035NCI NIH HHS N01-PC-35139NIEHS NIH HHS P30 ES007048
6 · The paper itself

Abstract

Human immunodeficiency virus (HIV) infection substantially elevates diffuse large B-cell lymphoma (DLBCL) risk, but its impact on the distinct DLBCL subtypes defined by cell of origin is unclear. We compared DLBCL molecular characteristics and prognosis in 51 HIV-infected and 116 HIV-uninfected cases diagnosed during 1977-2003. Using immunohistochemistry to classify cell of origin based on the Tally algorithm, activated B-cell (ABC)-DLBCL was substantially more common in HIV-infected (83%) than in HIV-uninfected (54%) cases (p < 0.001). Epstein-Barr virus (EBV) was detected in 63% of DLBCLs in HIV-infected cases, occurring almost exclusively in ABC-DLBCL (74% vs. 13% of germinal center B-cell [GCB]-DLBCL, p = 0.002), but was rarely detected in DLBCLs among HIV-uninfected cases (3%). Among HIV-uninfected cases, MYC/IgH [t(8;14)(q24;q32)] and IgH/BCL2 [t(14;18)(q32;q21)] translocations were significantly more common and BCL6/IgH [t(3;14)(q27;q32)] significantly less common in GCB-DLBCL than in ABC-DLBCL (p = 0.010, < 0.001 and = 0.039, respectively). Among HIV-infected cases, translocations other than MYC/IgH [t(8;14)(q24;q32)] (21%) were rare (≤ 6%) and unrelated to cell of origin. ABC-DLBCL was associated with adverse overall survival compared with GCB-DLBCL regardless of HIV status (pHIV-infected = 0.066; pHIV-uninfected = 0.038). Our data demonstrate key differences in the molecular characteristics, cell of origin and prognosis of DLBCL by HIV status in the pre-highly active antiretroviral therapy (HAART) and pre-rituximab era, supporting biologic differences in lymphomagenesis in the presence of HIV.

Indexed as

AdultAgedAged, 80 and overAntiretroviral Therapy, Highly ActiveBiomarkers, TumorCell Transformation, NeoplasticFemaleGerminal CenterHIV InfectionsHumansImmunohistochemistryLymphoma, Large B-Cell, DiffuseMaleMiddle AgedYoung AdultBiomarkers, Tumor

Identifiers

PMID23772639
PMCPMC3936016
OpenAlexW2128216419

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.